1. Short title This Act may be cited as the Fair Access for Safe and Timely Generics Act of 2017 or the FAST Generics Act of 2017 . 2. Findings The Congress finds the following: (1) Reference product license or approval holders are restricting competitive access to reference products by sponsors seeking to develop drugs, generic drugs, and biosimilars under section 505(b)(2) or 505(j) of the Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(b)(2) and 355(j)) and under section 351(k) of the Public Health Service Act ( 42 U.S.C. 262(k) ). These restrictions are deterring and delaying development of drugs, generic drugs and biosimilars by extending lawful patent-based monopolies beyond their lawful patent life. (2) The enforcement provisions set forth in section 505–1(f)(8) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1(f)(8) ) have not been sufficient to prevent anti-competitive practices that interfere with access to reference products which is necessary for the timely development of affordable drugs, generic drugs, and biosimilars. (3) There is not a regulatory structure in place that is sufficient to deter or remedy the anti-competitive harm that results when— (A) access to reference products is restricted to sponsors developing drugs, generic drugs, or biosimilars in accordance with section 505(b)(2) or 505(j) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(b)(2) or 355(j)), and section 351(k) of the Public Health Service Act ( 42 U.S.C. 262(k) ), respectively